Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:42:30.502Z.
Calculation as of: 2026-10-06T19:42:30.502Z.
Quote observation: 2026-10-06T19:39:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$10.46M
PS Ratio
N/A
TTM Avg
32.91
3Y Avg
62.07
5Y Avg
66.46
Market Cap
$11.29M
PS Ratio
112.92
TTM Avg
104.86
3Y Avg
73.15
5Y Avg
73.15
Market Cap
$10.01M
PS Ratio
182.06
TTM Avg
604.36
3Y Avg
203.60
5Y Avg
133.69
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.13M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.46M | N/A | 32.91 | 62.07 | 66.46 |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A | 56.92 | 56.92 | 56.92 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.29M | 112.92 | 104.86 | 73.15 | 73.15 |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.05M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.10M | 0.46 | 0.51 | 1.36 | 4.08 |
| Senti Biosciences, Inc. (SNTI)vs › | $10.01M | 182.06 | 604.36 | 203.60 | 133.69 |
| Polyrizon Ltd. (PLRZ)vs › | $10.41M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.92M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $10.94M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from USD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
